---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Drug interactions questions"
description: "Drug interactions questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can COPD patients on Trelegy take beta-blockers? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Drug interactions questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Drug interactions questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta/drug-interactions).

## Drug interactions

<a id="trelegy-beta-blockers"></a>

### Can COPD patients on Trelegy take beta-blockers?

> “Beta-blockers not only block the pulmonary effect of beta-agonists, such as vilanterol, but may 
> also produce severe bronchospasm in patients with COPD or asthma. Therefore, patients with 
> COPD or asthma should not normally be treated with beta-blockers. However, under certain 
> circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking 
> agents for these patients; cardioselective beta-blockers could be considered, although they should 
> be administered with caution.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=16)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
